Leishmaniasis
Recent clinical, regulatory, research and industry developments relating to this disease.
Molecular monitoring of insecticide resistance in major disease vectors in Armenia.
Anti-trypanosomatid drug discovery: progress and challenges.
The increase in risk factors for leishmaniasis worldwide.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q4 2029.
Clinical MilestonesViewHide
- 2025-11-01Effectiveness of Ciprofloxacin Intralesional Injection in the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate: a Parallel Groups Comparative TrialPrimary completion
- 2025-11-01The Clinical Effect of Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis: Single Arm Open-label TrialPrimary completion
- 2026-04-02ClinicalRandomized Blinded Clinical Trial to Evaluate the Safety and Efficacy of Arnica Tincture in the Topical Treatment of Cutaneous Leishmaniasis.Results expected Q4 2029
- 2025-11-01ClinicalEffectiveness of Ciprofloxacin Intralesional Injection in the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate: a Parallel Groups Comparative TrialPrimary completion
- 2025-11-01ClinicalThe Clinical Effect of Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis: Single Arm Open-label TrialPrimary completion
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Leishmaniasis2
- Aedes1
- Anopheles1
- Chagas Disease1
- COVID-191
- Culex1
- Insecticides1
- Malaria1
Leading journals5
- BMJ global health1
- Medical and veterinary entomology1
- Nature reviews. Microbiology1
- Parasites & vectors1
- Transactions of the Royal Society of Tropical Medicine and Hygiene1
Leading researchers8
- Awotiwon A1
- Babayan L1
- Báfica ACMF1
- Balaska S1
- Bichaud L1
- Charrel RN1
- Cornick RV1
- da Silveira JPM1
Affiliations (unnormalised)6
- Clinic Management Coordination1
- Institute of Molecular Biology and Biotechnology1
- National Center for Disease Control and Prevention1
- Pesticide Science Laboratory1
- School of Life Course & Population Sciences1
- University of Cape Town1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Leishmaniasis is an infectious disease caused by protozoa of the genus Leishmania. It includes four major clinical forms: cutaneous, diffuse cutaneous, mucocutaneous, and visceral leishmaniasis.
Leishmaniasis is caused by infection with species of the protozoan genus Leishmania. Transmission is associated with phlebotomine sandflies, which are proven or suspected vectors for human leishmaniases.
The disease results from infection by Leishmania protozoa, with clinical expression varying by species and form of disease. The literature grounding provided here supports vector-borne transmission and the existence of distinct cutaneous and visceral disease entities, but does not provide further mechanistic detail.
Risk is increased by environmental and social conditions that favor transmission, including inadequate housing, drinking-water, and sanitation in rapidly growing urban areas. Human migration, deforestation, urbanization, increased sandfly breeding sites and blood sources, and interruption of vector control activities are also described as contributors to spread.
Drug therapy is a standard treatment modality for leishmaniasis. The supplied grounding supports treatment at the drug-class or modality level only and does not specify particular agents or regimens.
AI-generated summary grounded in MeSH and 3 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.